Company news
Niagen Bioscience, Inc. (NASDAQ:NAGE) news
Niagen Bioscience, Inc. news releases on 6ix. Latest, Oct 6, 2026: Niagen Bioscience to Present at LD Micro 20th Annual Main Event
Press releases & updates
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
October 6, 2026
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®" a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
October 1, 2026
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
September 30, 2026
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
September 29, 2026
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
September 21, 2026
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
September 17, 2026
Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
September 10, 2026
Niagen Bioscience to Present at Longevity Investors Conference
September 2, 2026
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
August 26, 2026
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
August 20, 2026
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
August 12, 2026
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
August 6, 2026
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
August 4, 2026
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
August 3, 2026
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
July 28, 2026
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
July 27, 2026
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
July 16, 2026
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
July 13, 2026
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
July 9, 2026
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
July 8, 2026
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
June 3, 2026
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
June 1, 2026
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
May 8, 2026
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
May 6, 2026
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
May 4, 2026
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
April 28, 2026
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
April 22, 2026
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
April 8, 2026
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpa World, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
April 1, 2026
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
March 30, 2026
Niagen Bioscience Increases Share Repurchase Program to $20 Million
March 18, 2026
Niagen Bioscience to Present at the 38th Annual ROTH Conference
March 17, 2026
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
March 17, 2026
Niagen Bioscience Launches Niagen(R) Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud, From Tru Niagen Powered by Patented Niagen(R)
March 11, 2026
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
March 9, 2026
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
March 3, 2026
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
February 26, 2026
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
February 25, 2026
Niagen Bioscience is the Premiere Sponsor of the Inaugural "NAD for Health: Opportunities & Challenges" Conference Hosted by the University of Copenhagen
February 9, 2026
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen
February 8, 2026
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
February 6, 2026
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
January 15, 2026
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
December 21, 2025
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
November 12, 2025
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
November 11, 2025
Niagen Bioscience Announces $10 Million Share Repurchase Program
November 5, 2025
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
November 3, 2025
Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 20, 2025
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
October 5, 2025